These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 20345722

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ, Sidonio RF, O'Day K, Runken MC, Meyer K, Spears J.
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [Abstract] [Full Text] [Related]

  • 4. Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.
    Batorova A, Jankovicova D, Morongova A, Bubanska E, Prigancova T, Horakova J, Machyniakova M, Cervenka J, Chandoga J, Böhmer D, Mistrik M.
    Semin Thromb Hemost; 2016 Jul; 42(5):550-62. PubMed ID: 27235830
    [Abstract] [Full Text] [Related]

  • 5. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
    Montalvão SA, Tucunduva AC, Siqueira LH, Sambo AL, Medina SS, Ozelo MC.
    Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A.
    Kelly KM, Butler RB, Farace L, Cohen AR, Manno CS.
    J Pediatr; 1997 Apr; 130(4):537-40. PubMed ID: 9108849
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H, Yoshioka A, Shima M, Tanaka I, Koshihara K, Fukutake K, Fujimaki M.
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
    Musso R.
    Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
    [Abstract] [Full Text] [Related]

  • 13. The uptake of recombinant Factor VIII in the Netherlands.
    Zwart-van Rijkom JE, Plug I, Rosendaal FR, Leufkens HG, Broekmans AW, Study Group Haemophilia in The Netherlands.
    Br J Haematol; 2002 Nov; 119(2):332-41. PubMed ID: 12406065
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM.
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.
    Ettingshausen CE, Kreuz W.
    Haemophilia; 2006 Dec; 12 Suppl 6():102-6. PubMed ID: 17123402
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.